Novel Technologies

Novel Technologies

Novel technologies have the potential to change inheritable blood and bleeding disorders forever. Read about gene therapy and other developments.

Assessing the My Life, Our Future Genotyping Project A recent article in the journal Haemophilia analyzed the My Life, Our...
On February 23 and 24, an international group of researchers from universities, industry and government gathered in Washington, DC, for...
All of the funding for the JGP program comes from donations from NHF chapters and individuals.
We strive toward enrolling 2,000 confirmed hemophilia carriers in the MLOF Research Repository.
Like hepatitis C, hepatitis B is a viral infection in the liver. The infection can be acute or chronic, in...
The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose...
Two subcutaneous therapies are currently being investigated.
MLOF is open to all people with hemophilia A and B.
More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.
The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.
Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.
An update on FVII gene therapy and more.
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.